查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586172

細胞和基因療法市場：按產品、遞送方法、應用和最終用戶 - 2025-2030 年全球預測

Cell & Gene Therapy Market by Product (Cell Therapy, Gene Therapy), Delivery Method (Ex Vivo, In Vivo), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞和基因治療市場2023年估值為277億美元，預計2024年將達到346.3億美元，複合年成長率為25.39%，預計到2030年將達到1350.4億美元。

細胞和基因療法（CGT）涉及使用生物療法將遺傳物質引入患者的細胞中以治療或預防疾病。這一發展中的領域對於解決未滿足的醫療需求至關重要，特別是在罕見遺傳疾病、癌症和某些慢性病方面。增加對基因組研究、先進臨床試驗的投資以及加快監管途徑（例如 FDA 的再生醫學先進療法指定）是成長的催化劑。應用範圍從腫瘤學（其中 CAR-T 等治療方法已顯示出令人印象深刻的緩解率）到再生醫學（治療神經系統和心血管疾病）。潛在的最終用途擴展到醫院、癌症治療中心和專科診所。由於 CRISPR 技術的進步、個人化醫療方法以及慢性病盛行率的增加，該市場正在經歷顯著成長。擴大 CGT 涵蓋的適應症、建立強大的製造能力以及與生物製藥公司合作以增強治療特異性和遞送機制方面存在機會。然而，挑戰依然存在，包括高昂的開發和處理成本、複雜的製造流程以及嚴格的監管要求。此外，對基因改造和潛在長期影響的倫理擔憂也構成了障礙。為了促進創新，現成的同種異體療法、用於高效基因傳遞的增強載體設計以及人工智慧主導的標靶治療藥物發現等研究可能會帶來重大進展。此外，可以透過策略性定價模型和徹底的公私合營關係來增強患者的可及性，從而解決市場障礙。目前，市場成長充滿活力，受到快速技術進步和不斷上升的核准率的推動，但受到生產可擴展性問題和報銷狀態波動的限制。克服交付挑戰、最佳化製造流程以及優先考慮以患者為中心的模型對於利用細胞和基因治療領域快速成長的機會至關重要。

主要市場統計
基準年[2023] 277億美元
預測年份 [2024] 346.3億美元
預測年份 [2030] 1350.4億美元
複合年成長率（%） 25.39%

市場動態：針對快速發展的細胞和基因治療市場揭示的關鍵市場見解

供需的動態交互作用正在改變細胞和基因治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率上升和基因治療的重要性
    • 隨著醫療保健支出的增加，人們對基因和細胞療法的認知也不斷增強
    • 臨床試驗數量大幅增加，政府核准數量增加
  • 市場限制因素
    • 與基因和細胞治療相關的高成本
  • 市場機會
    • 細胞和基因發育中先進分析技術的出現
    • 增加製藥和生物製藥研究的投資
  • 市場挑戰
    • 細胞/基因治療的報銷政策不完善

波特的五力：駕馭細胞與基因治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細胞和基因治療市場的外部影響

外部宏觀環境因素在塑造細胞和基因治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解細胞和基因治療市場的競爭狀況

細胞和基因治療市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣細胞與基因治療市場供應商績效評估

FPNV定位矩陣是評估細胞和基因療法市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製細胞和基因治療市場的成功之路

細胞和基因治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的增加和基因治療的重要性
      • 人們對基因和細胞療法的認知不斷增強，醫療保健成本不斷上升
      • 臨床試驗數量大幅增加，政府核准數量增加
    • 抑制因素
      • 與基因和細胞治療相關的高成本
    • 機會
      • 細胞和基因開發中先進分析技術的出現
      • 增加製藥和生物製藥研究的投資
    • 任務
      • 報銷政策不適用於細胞和基因治療
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章細胞/基因治療市場：依產品

  • 細胞療法
  • 基因治療

第7章以遞送方式分類的細胞和基因治療市場

  • 體外
  • In vivo

第8章細胞/基因治療市場：依應用分類

  • 皮膚科
  • 肌肉骨骼
  • 腫瘤學

第9章細胞/基因治療市場：依最終用戶分類

  • 門診手術中心
  • 癌症護理中心
  • 醫院
  • 創傷護理中心

第10章美洲細胞與基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太細胞與基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的細胞和基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • Adaptimmune Limited
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Gene Therapies
  • Beacon Therapeutics Limited
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Immuneel Therapeutics Private Limited
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Uniqure NV
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market was valued at USD 27.70 billion in 2023, expected to reach USD 34.63 billion in 2024, and is projected to grow at a CAGR of 25.39%, to USD 135.04 billion by 2030.

Cell and gene therapy (CGT) encompasses the use of biological treatments that modify or introduce genetic material into a patient's cells to treat or prevent disease. This evolving sector is notably vital for addressing unmet medical needs, especially for rare genetic disorders, cancers, and certain chronic conditions. Increasing investments in genomic research, advanced clinical trials, and the acceleration through expedited regulatory pathways like the FDA's regenerative medicine advanced therapy designation have catalyzed growth. Applications span from oncology, where therapies like CAR-T have shown remarkable remission rates, to regenerative medicine treating neurological disorders and cardiovascular diseases. The end-use potential extends to hospitals, cancer treatment centers, and specialized clinics. The market is experiencing significant growth driven by advances in CRISPR technology, personalized medicine approaches, and an increasing prevalence of chronic diseases. Opportunities lie in expanding the indications covered by CGT, establishing robust manufacturing capabilities, and biopharma collaborations to enhance therapy specificity and delivery mechanisms. However, challenges remain, including high development and therapy costs, complex manufacturing processes, and strict regulatory requirements. Additionally, ethical concerns over genetic modifications and potential long-term impacts pose hurdles. To foster innovation, research into off-the-shelf allogeneic therapies, enhanced vector designs for efficient gene delivery, and AI-driven drug discovery for targeted therapies can provide significant advancements. Furthermore, enhancing patient access through strategic pricing models and in-depth public-private partnerships can address market barriers. Market growth is currently dynamic, spurred by rapid technological advancements and growing approval rates, yet tempered by production scalability issues and variable reimbursement landscapes. Moving forward, a focus on overcoming delivery challenges, optimizing manufacturing processes, and prioritizing patient-centric models will be pivotal in capitalizing on the burgeoning opportunities of the cell and gene therapy sector.

KEY MARKET STATISTICS
Base Year [2023] USD 27.70 billion
Estimated Year [2024] USD 34.63 billion
Forecast Year [2030] USD 135.04 billion
CAGR (%) 25.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Market

The Cell & Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and significance for gene therapy treatment
    • Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
    • Significant growth in numbers of clinical trials and increasing governmental approvals
  • Market Restraints
    • High costs asscoiated with the gene and cell therapy treatment
  • Market Opportunities
    • Emergence of advanced analytical technologies in development of cell & gene
    • Rising investments in pharmaceutical and biopharmaceutical research
  • Market Challenges
    • Unavailability of reimbursement policies for cell & gene therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Market

A detailed market share analysis in the Cell & Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Market

A strategic analysis of the Cell & Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Limited, AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., bluebird bio, Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Immuneel Therapeutics Private Limited, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cell Therapy and Gene Therapy.
  • Based on Delivery Method, market is studied across Ex Vivo and In Vivo.
  • Based on Application, market is studied across Dermatology, Musculoskeletal, and Oncology.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Care Centers, Hospitals, and Wound Care Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and significance for gene therapy treatment
      • 5.1.1.2. Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
      • 5.1.1.3. Significant growth in numbers of clinical trials and increasing governmental approvals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs asscoiated with the gene and cell therapy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of advanced analytical technologies in development of cell & gene
      • 5.1.3.2. Rising investments in pharmaceutical and biopharmaceutical research
    • 5.1.4. Challenges
      • 5.1.4.1. Unavailability of reimbursement policies for cell & gene therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy

7. Cell & Gene Therapy Market, by Delivery Method

  • 7.1. Introduction
  • 7.2. Ex Vivo
  • 7.3. In Vivo

8. Cell & Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Dermatology
  • 8.3. Musculoskeletal
  • 8.4. Oncology

9. Cell & Gene Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Cancer Care Centers
  • 9.4. Hospitals
  • 9.5. Wound Care Centers

10. Americas Cell & Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Adaptimmune Limited
  • 3. AGC Biologics
  • 4. Alnylam Pharmaceuticals, Inc.
  • 5. American Gene Technologies Inc.
  • 6. Amgen Inc.
  • 7. AnGes, Inc.
  • 8. Astellas Gene Therapies
  • 9. Beacon Therapeutics Limited
  • 10. Biogen Inc.
  • 11. bluebird bio, Inc.
  • 12. Cellectis SA
  • 13. Editas Medicine, Inc.
  • 14. F. Hoffmann-La Roche Ltd
  • 15. Immuneel Therapeutics Private Limited
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Merck KGaA
  • 18. Mustang Bio, Inc.
  • 19. Novartis AG
  • 20. Orchard Therapeutics PLC
  • 21. Poseida Therapeutics, Inc.
  • 22. Sangamo Therapeutics, Inc.
  • 23. Sarepta Therapeutics, Inc.
  • 24. Sibiono GeneTech Co. Ltd.
  • 25. Uniqure N.V.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023